Journal Home > Volume 11 , Issue 10
Nano Research 2018, 11(10): 4999-5016 https://doi.org/10.1007/s12274-018-2083-z
Review Article | Issue | Published: 17 May 2018

Advances in targeted nanotherapeutics: From bioconjugation to biomimicry

Show Author's Information Danielle M. Valcourt1,  Jenna Harris2,  Rachel S. Riley1,  Megan Dang1,  Jianxin Wang1,  Emily S. Day1,2,3( )
161 Colburn LabDepartment of Biomedical EngineeringUniversity of DelawareNewarkDE19716USA
201 DuPont HallDepartment of Materials Science & EngineeringUniversity of DelawareNewarkDE19716USA
4701 Ogletown Stanton RoadHelen F. Graham Cancer Center & Research InstituteNewarkDE19713USA
Keywords:
nanoparticles, cancer, targeting, biomimicry, bioconjugation, delivery
Cite this article:
Valcourt DM, Harris J, Riley RS, et al. Advances in targeted nanotherapeutics: From bioconjugation to biomimicry. Nano Research, 2018, 11(10): 4999-5016. https://doi.org/10.1007/s12274-018-2083-z
Download citation
EndNote(RIS)
BibTeX

694

Views

25

Downloads

Citations

59

Crossref

N/A

WoS

58

Scopus

0

CSCD

Abstract Full text About this article

Since the emergence of cancer nanomedicine, researchers have had intense interest in developing nanoparticles (NPs) that can specifically target diseased sites while avoiding healthy tissue to mitigate the off-target effects seen with conventional treatments like chemotherapy. Initial endeavors focused on the bioconjugation of targeting agents to NPs, and more recently, researchers have begun to develop biomimetic NP platforms that can avoid immune recognition to maximally accumulate in tumors. In this review, we describe the advantages and limitations of each of these targeting strategies. First, we review developments in bioconjugation strategies, where NPs are coated with biomolecules such as antibodies, aptamers, peptides, and small molecules to enable cell-specific binding. While bioconjugated NPs offer many exciting features and have improved pharmacokinetics and biodistribution relative to unmodified NPs, they are still recognized by the body as "foreign", resulting in their clearance by the mononuclear phagocytic system (MPS). To overcome this limitation, researchers have recently begun to investigate biomimetic approaches that can hide NPs from immune recognition and reduce clearance by the MPS. These biomimetic NPs fall into two distinct categories: synthetic NPs that present naturally occurring structures, and NPs that are completely disguised by natural structures. Overall, bioconjugated and biomimetic NPs have substantial potential to improve upon conventional treatments by reducing off-target effects through site-specific delivery, and they show great promise for future standards of care. Here, we provide a summary of each strategy, discuss considerations for their design moving forward, and highlight their potential clinical impact on cancer therapy.


menu
Abstract
Full text
Outline
About this article

Advances in targeted nanotherapeutics: From bioconjugation to biomimicry

Show Author's information Danielle M. Valcourt1, Jenna Harris2, Rachel S. Riley1, Megan Dang1, Jianxin Wang1, Emily S. Day1,2,3( )
161 Colburn LabDepartment of Biomedical EngineeringUniversity of DelawareNewarkDE19716USA
201 DuPont HallDepartment of Materials Science & EngineeringUniversity of DelawareNewarkDE19716USA
4701 Ogletown Stanton RoadHelen F. Graham Cancer Center & Research InstituteNewarkDE19713USA

Abstract

Since the emergence of cancer nanomedicine, researchers have had intense interest in developing nanoparticles (NPs) that can specifically target diseased sites while avoiding healthy tissue to mitigate the off-target effects seen with conventional treatments like chemotherapy. Initial endeavors focused on the bioconjugation of targeting agents to NPs, and more recently, researchers have begun to develop biomimetic NP platforms that can avoid immune recognition to maximally accumulate in tumors. In this review, we describe the advantages and limitations of each of these targeting strategies. First, we review developments in bioconjugation strategies, where NPs are coated with biomolecules such as antibodies, aptamers, peptides, and small molecules to enable cell-specific binding. While bioconjugated NPs offer many exciting features and have improved pharmacokinetics and biodistribution relative to unmodified NPs, they are still recognized by the body as "foreign", resulting in their clearance by the mononuclear phagocytic system (MPS). To overcome this limitation, researchers have recently begun to investigate biomimetic approaches that can hide NPs from immune recognition and reduce clearance by the MPS. These biomimetic NPs fall into two distinct categories: synthetic NPs that present naturally occurring structures, and NPs that are completely disguised by natural structures. Overall, bioconjugated and biomimetic NPs have substantial potential to improve upon conventional treatments by reducing off-target effects through site-specific delivery, and they show great promise for future standards of care. Here, we provide a summary of each strategy, discuss considerations for their design moving forward, and highlight their potential clinical impact on cancer therapy.

Keywords: nanoparticles, cancer, targeting, biomimicry, bioconjugation, delivery

References(120)

1

Wang, Z. L.; Qiao, R. R.; Tang, N.; Lu, Z. W.; Wang, H.; Zhang, Z. X.; Xue, X. D.; Huang, Z. Y.; Zhang, S. R.; Zhang, G. X. et al. Active targeting theranostic iron oxide nanoparticles for MRI and magnetic resonance–guided focused ultrasound ablation of lung cancer. Biomaterials 2017, 127, 25–35.
DOI Google Scholar
2

El–Sayed, I. H.; Huang, X.; El–Sayed, M. A. Selective laser photo–thermal therapy of epithelial carcinoma using anti–EGFR antibody conjugated gold nanoparticles. Cancer Lett. 2006, 239, 129–135.
DOI Google Scholar
3

Damodaran, S.; Olson, E. M. Targeting the human epidermal growth factor receptor 2 pathway in breast cancer. Hosp. Pract. 2012, 40, 7–15.
DOI Google Scholar
4

Dehaini, D.; Fang, R. H.; Zhang, L. F. Biomimetic strategies for targeted nanoparticle delivery. Bioeng. Transl. Med. 2016, 1, 30–46.
DOI Google Scholar
5

Byrne, J. D.; Betancourt, T.; Brannon–Peppas, L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv. Drug Deliv. Rev. 2008, 60, 1615–1626.
DOI Google Scholar
6

Wang, M.; Thanou, M. Targeting nanoparticles to cancer. Pharmacol. Res. 2010, 62, 90–99.
DOI Google Scholar
7

Riley, R. S.; Day, E. S. Gold nanoparticle–mediated photothermal therapy: Applications and opportunities for multimodal cancer treatment. WIREs Nanomed. Nanobiotechnol. 2017, 9, e1449.
DOI Google Scholar
8

Kumar, A.; Ma, H. L.; Zhang, X.; Huang, K. Y.; Jin, S. B.; Liu, J.; Wei, T.; Cao, W. P.; Zou, G. Z.; Liang, X. –J. Gold nanoparticles functionalized with therapeutic and targeted peptides for cancer treatment. Biomaterials 2012, 33, 1180–1189.
DOI Google Scholar
9

Dam, D. H. M.; Culver, K. S. B.; Odom, T. W. Grafting aptamers onto gold nanostars increases in vitro efficacy in a wide range of cancer cell types. Mol. Pharm. 2014, 11, 580–587.
DOI Google Scholar
10

Lowery, A. R.; Gobin, A. M.; Day, E. S.; Halas, N. J.; West, J. L. Immunonanoshells for targeted photothermal ablation of tumor cells. Int. J. Nanomedicine 2006, 1, 149–154.
DOI Google Scholar
11

Loo, C.; Lowery, A.; Halas, N.; West, J.; Drezek, R. Immunotargeted nanoshells for integrated cancer imaging and therapy. Nano Lett. 2005, 5, 709–711.
DOI Google Scholar
12

Brannon–Peppas, L.; Blanchette, J. O. Nanoparticle and targeted systems for cancer therapy. Adv. Drug Deliv. Rev. 2012, 64, 206–212.
DOI Google Scholar
13

Hou, Y.; Zhou, J.; Gao, Z. Y.; Sun, X. Y.; Liu, C. Y.; Shangguan, D. H.; Yang, W. S.; Gao, M. Y. Proteaseactivated ratiometric fluorescent probe for pH mapping of malignant tumors. ACS Nano 2015, 9, 3199–3205.
DOI Google Scholar
14

Jeong, S.; Park, J. Y.; Cha, M. G.; Chang, H. J.; Kim, Y. I.; Kim, H. –M.; Jun, B. –H.; Lee, D. S.; Lee, Y. –S.; Jeong, J. M. et al. Highly robust and optimized conjugation of antibodies to nanoparticles using quantitatively validated protocols. Nanoscale 2017, 9, 2548–2555.
DOI Google Scholar
15

Kumar, S.; Aaron, J.; Sokolov, K. Directional conjugation of antibodies to nanoparticles for synthesis of multiplexed optical contrast agents with both delivery and targeting moieties. Nat. Protoc. 2008, 3, 314–320.
DOI Google Scholar
16

Joshi, P. P.; Yoon, S. J.; Hardin, W. G.; Emelianov, S.; Sokolov, K. V. Conjugation of antibodies to gold nanorods through Fc portion: Synthesis and molecular specific imaging. Bioconjug. Chem. 2013, 24, 878–888.
DOI Google Scholar
17

Parolo, C.; de la Escosura–Muñiz, A.; Polo, E.; Grazú, V.; de la Fuente, J. M.; Merkoçi, A. Design, preparation, and evaluation of a fixed–orientation antibody/gold–nanoparticle conjugate as an immunosensing label. ACS Appl. Mater. Interfaces 2013, 5, 10753–10759.
DOI Google Scholar
18
Moynihan, T. J. HER2–positive breast cancer: What is it? https://www.mayoclinic.org/breast–cancer/expert–answers/faq–20058066 (accessed Mar 14, 2018).
19

Master, A. M.; Sen Gupta, A. EGF receptor–targeted nanocarriers for enhanced cancer treatment. Nanomedicine 2012, 7, 1895–1906.
DOI Google Scholar
20

Billingsley, M. M.; Riley, R. S.; Day, E. S. Antibodynanoparticle conjugates to enhance the sensitivity of ELISAbased detection methods. PLoS One 2017, 12, e0177592.
DOI Google Scholar
21

Bae, K. H.; Lee, K.; Kim, C.; Park, T. G. Surface functionalized hollow manganese oxide nanoparticles for cancer targeted siRNA delivery and magnetic resonance imaging. Biomaterials 2011, 32, 176–184.
DOI Google Scholar
22

Palanca–Wessels, M. C.; Booth, G. C.; Convertine, A. J.; Lundy, B. B.; Berguig, G. Y.; Press, M. F.; Stayton, P. S.; Press, O. W. Antibody targeting facilitates effective intratumoral siRNA nanoparticle delivery to HER2–overexpressing cancer cells. Oncotarget 2016, 7, 9561–9575.
DOI Google Scholar
23

Dilnawaz, F.; Singh, A.; Mohanty, C.; Sahoo, S. K. Dual drug loaded superparamagnetic iron oxide nanoparticles for targeted cancer therapy. Biomaterials 2010, 31, 3694–3706.
DOI Google Scholar
24

Riley, R. S.; Day, E. S. Frizzled7 antibody–functionalized nanoshells enable multivalent binding for Wnt signaling inhibition in triple negative breast cancer cells. Small 2017, 13, 1700544.
DOI Google Scholar
25

Scott, A. M.; Wolchok, J. D.; Old, L. J. Antibody therapy of cancer. Nat. Rev. Cancer 2012, 12, 278–287.
DOI Google Scholar
26

Jiang, W.; Kim, B. Y. S.; Rutka, J. T.; Chan, W. C. W. Nanoparticle–mediated cellular response is size–dependent. Nat. Nanotechnol. 2008, 3, 145–150.
DOI Google Scholar
27

Schardt, J. S.; Oubaid, J. M.; Williams, S. C.; Howard, J. L.; Aloimonos, C. M.; Bookstaver, M. L.; Lamichhane, T. N.; Sokic, S.; Liyasova, M. S.; O'Neill, M. et al. Engineered multivalency enhances affibody–based HER3 inhibition and downregulation in cancer cells. Mol. Pharmacol. 2017, 14, 1047–1056.
DOI Google Scholar
28

Prakash, J. S.; Rajamanickam, K. Aptamers and their significant role in cancer therapy and diagnosis. Biomedicines 2015, 3, 248–269.
DOI Google Scholar
29

Wu, X.; Chen, J.; Wu, M.; Zhao, J. X. Aptamers: Active targeting ligands for cancer diagnosis and therapy. Theranostics 2015, 5, 322–344.
DOI Google Scholar
30

Hicke, B. J.; Stephens, A. W.; Gould, T.; Chang, Y. –F.; Lynott, C. K.; Heil, J.; Borkowski, S.; Hilger, C. –S.; Cook, G.; Warren, S. et al. Tumor targeting by an aptamer. J. Nucl. Med. 2006, 47, 668–678.
Google Scholar
31

Valetti, S.; Mura, S.; Noiray, M.; Arpicco, S.; Dosio, F.; Vergnaud, J.; Desmaële, D.; Stella, B.; Couvreur, P. Peptide conjugation: Before or after nanoparticle formation? Bioconjug. Chem. 2014, 25, 1971–1983.
DOI Google Scholar
32

Choi, H. S.; Liu, W. H.; Liu, F. B.; Nasr, K.; Misra, P.; Bawendi, M. G.; Frangioni, J. V. Design considerations for tumour–targeted nanoparticles. Nat. Nanotechnol. 2010, 5, 42–47.
DOI Google Scholar
33

Nasongkla, N.; Bey, E.; Ren, J. M.; Ai, H.; Khemtong, C.; Guthi, J. S.; Chin, S. F.; Sherry, A. D.; Boothman, D. A.; Gao, J. M. Multifunctional polymeric micelles as cancertargeted, MRI–ultrasensitive drug delivery systems. Nano Lett. 2006, 6, 2427–2430.
DOI Google Scholar
34

Xiong, X. B.; Lavasanifar, A. Traceable multifunctional micellar nanocarriers for cancer–targeted co–delivery of MDR–1 siRNA and doxorubicin. ACS Nano 2011, 5, 5202–5213.
DOI Google Scholar
35

Milane, L.; Duan, Z. F.; Amiji, M. Therapeutic efficacy and safety of paclitaxel/lonidamine loaded EGFR–targeted nanoparticles for the treatment of multi–drug resistant cancer. PLoS One 2011, 6, e24075.
DOI Google Scholar
36

Milane, L.; Duan, Z. F.; Amiji, M. Pharmacokinetics and biodistribution of lonidamine/paclitaxel loaded, EGFR–targeted nanoparticles in an orthotopic animal model of multi–drug resistant breast cancer. Nanomedicine 2011, 7, 435–444.
DOI Google Scholar
37

Reddy, G. R.; Bhojani, M. S.; McConville, P.; Moody, J.; Moffat, B. A.; Hall, D. E.; Kim, G.; Koo, Y. E. L.; Woolliscroft, M. J.; Sugai, J. V. et al. Vascular targeted nanoparticles for imaging and treatment of brain tumors. Clin. Cancer Res. 2006, 12, 6677–6686.
DOI Google Scholar
38

Sanna, V.; Nurra, S.; Pala, N.; Marceddu, S.; Pathania, D.; Neamati, N.; Sechi, M. Targeted nanoparticles for the delivery of novel bioactive molecules to pancreatic cancer cells. J. Med. Chem. 2016, 59, 5209–5220.
DOI Google Scholar
39

Aina, O. H.; Sroka, T. C.; Chen, M. L.; Lam, K. S. Therapeutic cancer targeting peptides. Biopolymers 2002, 66, 184–199.
DOI Google Scholar
40

Juliano, R. L.; Alam, R.; Dixit, V.; Kang, H. M. Celltargeting and cell–penetrating peptides for delivery of therapeutic and imaging agents. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2009, 1, 324–336.
DOI Google Scholar
41

Zwicke, G. L.; Mansoori, G. A.; Jeffery, C. J. Utilizing the folate receptor for active targeting of cancer nanotherapeutics. Nano Rev. 2012, 3, 18496.
DOI Google Scholar
42

Bazak, R.; Houri, M.; El Achy, S.; Kamel, S.; Refaat, T. Cancer active targeting by nanoparticles: A comprehensive review of literature. J. Cancer Res. Clin. Oncol. 2015, 141, 769–784.
DOI Google Scholar
43

Wang, C.; Cheng, L.; Liu, Z. Drug delivery with upconversion nanoparticles for multi–functional targeted cancer cell imaging and therapy. Biomaterials 2011, 32, 1110–1120.
DOI Google Scholar
44

Liu, T.; Zeng, L. L.; Jiang, W. T.; Fu, Y. T.; Zheng, W. J.; Chen, T. F. Rational design of cancer–targeted selenium nanoparticles to antagonize multidrug resistance in cancer cells. Nanomedicine 2015, 11, 947–958.
DOI Google Scholar
45

Yu, B.; Li, X. L.; Zheng, W. J.; Feng, Y. X.; Wong, Y. –S.; Chen, T. F. PH–responsive cancer–targeted selenium nanoparticles: A transformable drug carrier with enhanced theranostic effects. J. Mater. Chem. B 2014, 2, 5409–5418.
DOI Google Scholar
46

Zhang, Q.; Wang, X. L.; Li, P. Z.; Nguyen, K. T.; Wang, X. J.; Luo, Z.; Zhang, H. C.; Tan, N. S.; Zhao, Y. L. Biocompatible, uniform, and redispersible mesoporous silica nanoparticles for cancer–targeted drug delivery in vivo. Adv. Funct. Mater. 2014, 24, 2450–2461.
DOI Google Scholar
47

Huang, Y. Y.; He, L. Z.; Liu, W.; Fan, C. D.; Zheng, W. J.; Wong, Y. S.; Chen, T. F. Selective cellular uptake and induction of apoptosis of cancer–targeted selenium nanoparticles. Biomaterials 2013, 34, 7106–7116.
DOI Google Scholar
48

Valencia, P. M.; Pridgen, E. M.; Rhee, M.; Langer, R.; Farokhzad, O. C.; Karnik, R. Microfluidic platform for combinatorial synthesis and optimization of targeted nanoparticles for cancer therapy. ACS Nano 2013, 7, 10671–10680.
DOI Google Scholar
49

Assanhou, A. G.; Li, W. Y.; Zhang, L.; Xue, L. J.; Kong, L. Y.; Sun, H. B.; Mo, R.; Zhang, C. Reversal of multidrug resistance by co–delivery of paclitaxel and lonidamine using a tpgs and hyaluronic acid dual–functionalized liposome for cancer treatment. Biomaterials 2015, 73, 284–295.
DOI Google Scholar
50

Xiao, B.; Han, M. K.; Viennois, E.; Wang, L. X.; Zhang, M. Z.; Si, X. Y.; Merlin, D. Hyaluronic acid–functionalized polymeric nanoparticles for colon cancer–targeted combination chemotherapy. Nanoscale 2015, 7, 17745–17755.
DOI Google Scholar
51

Dai, Q.; Walkey, C.; Chan, W. C. W. Polyethylene glycol backfilling mitigates the negative impact of the protein corona on nanoparticle cell targeting. Angew. Chem., Int. Ed. 2014, 53, 5093–5096.
DOI Google Scholar
52

Zhou, H.; Fan, Z. Y.; Deng, J. J.; Lemons, P. K.; Arhontoulis, D. C.; Bowne, W. B.; Cheng, H. Hyaluronidase in nanocarrier PEG shell for enhanced tumor penetration and highly efficient antitumor efficacy. Nano Lett. 2016, 16, 3268–3277.
DOI Google Scholar
53

Wilhelm, S.; Tavares, A. J.; Dai, Q.; Ohta, S.; Audet, J.; Dvorak, H. F.; Chan, W. C. W. Analysis of nanoparticle delivery to tumours. Nat. Rev. Mater. 2016, 1, 16014.
DOI Google Scholar
54

Hauert, S.; Berman, S.; Nagpal, R.; Bhatia, S. N. A computational framework for identifying design guidelines to increase the penetration of targeted nanoparticles into tumors. Nano Today 2013, 8, 566–576.
DOI Google Scholar
55

Kroll, A. V.; Fang, R. H.; Zhang, L. F. Biointerfacing and applications of cell membrane–coated nanoparticles. Bioconjug. Chem. 2017, 28, 23–32.
DOI Google Scholar
56

Verhoef, J. J.; Anchordoquy, T. J. Questioning the use of pegylation for drug delivery. Drug Deliv. Transl. Res. 2013, 3, 499–503.
DOI Google Scholar
57

Rodriguez, P. L.; Harada, T.; Christian, D. A.; Pantano, D. A.; Tsai, R. K.; Discher, D. E. Minimal "self" peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles. Science 2013, 339, 971–975.
DOI Google Scholar
58

Zhang, Z. H.; Chen, J.; Ding, L. L.; Jin, H.; Lovell, J. F.; Corbin, I. R.; Cao, W. G.; Lo, P. C.; Yang, M.; Tsao, M. S. et al. HDL–mimicking peptide–lipid nanoparticles with improved tumor targeting. Small 2010, 6, 430–437.
DOI Google Scholar
59

Li, J. H.; Ai, Y. W.; Wang, L. H.; Bu, P. C.; Sharkey, C. C.; Wu, Q. H.; Wun, B.; Roy, S.; Shen, X. L.; King, M. R. Targeted drug delivery to circulating tumor cells via platelet membrane–functionalized particles. Biomaterials 2016, 76, 52–65.
DOI Google Scholar
60

Rohovie, M. J.; Nagasawa, M.; Swartz, J. R. Virus–like particles: Next–generation nanoparticles for targeted therapeutic delivery. Bioeng. Transl. Med. 2017, 2, 43–57.
DOI Google Scholar
61

Dehaini, D.; Wei, X.; Fang, R. H.; Masson, S.; Angsantikul, P.; Luk, B. T.; Zhang, Y.; Ying, M.; Jiang, Y.; Kroll, A. V. et al. Erythrocyte–platelet hybrid membrane coating for enhanced nanoparticle functionalization. Adv. Mater. 2017, 29, 1606209.
DOI Google Scholar
62

Zhu, J. Y.; Zheng, D. W.; Zhang, M. K.; Yu, W. Y.; Qiu, W. X.; Hu, J. J.; Feng, J.; Zhang, X. Z. Preferential cancer cell self–recognition and tumor self–targeting by coating nanoparticles with homotypic cancer cell membranes. Nano Lett. 2016, 16, 5895–5901.
DOI Google Scholar
63

Hu, C. M. J.; Fang, R. H.; Wang, K. C.; Luk, B. T.; Thamphiwatana, S.; Dehaini, D.; Nguyen, P.; Angsantikul, P.; Wen, C. H.; Kroll, A. V. et al. Nanoparticle biointerfacing by platelet membrane cloaking. Nature 2015, 526, 118–121.
DOI Google Scholar
64

Hu, C. –M. J.; Zhang, L.; Aryal, S.; Cheung, C.; Fang, R. H.; Zhang, L. F. Erythrocyte membrane–camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc. Natl. Acad. Sci. USA 2011, 108, 10980–10985.
DOI Google Scholar
65

Luk, B. T.; Zhang, L. F. Cell membrane–camouflaged nanoparticles for drug delivery. J. Control. Release 2015, 220, 600–607.
DOI Google Scholar
66
McMahon, K. M.; Foi, L.; Angeloni, N. L.; Giles, F. J.; Gordon, L. I.; Thaxton, C. S. Synthetic high–density lipoprotein–like nanoparticles as cancer therapy. In Nanotechnology–Based Precision Tools for the Detection and Treatment of Cancer; Mirkin, C. A.; Meade, T. J.; Petrosko, S. H.; Stegh, A. H., Eds.; Springer: Switzerland, 2015; Vol. 166, pp 129–150.https://doi.org/10.1007/978-3-319-16555-4_6
DOI
67

Marrache, S.; Dhar, S. Biodegradable synthetic high–density lipoprotein nanoparticles for atherosclerosis. Proc. Natl. Acad. Sci. USA 2013, 110, 9445–9450.
DOI Google Scholar
68

McMahon, K. M.; Mutharasan, R. K.; Tripathy, S.; Veliceasa, D.; Bobeica, M.; Shumaker, D. K.; Luthi, A. J.; Helfand, B. T.; Ardehali, H.; Mirkin, C. A. et al. Biomimetic high density lipoprotein nanoparticles for nucleic acid delivery. Nano Lett. 2011, 11, 1208–1214.
DOI Google Scholar
69

Simberg, D.; Duza, T.; Park, J. H.; Essler, M.; Pilch, J.; Zhang, L. L.; Derfus, A. M.; Yang, M.; Hoffman, R. M.; Bhatia, S. et al. Biomimetic amplification of nanoparticle homing to tumors. Proc. Natl. Acad. Sci. USA 2007, 104, 932–936.
DOI Google Scholar
70

Wei, X. L.; Gao, J.; Fang, R. H.; Luk, B. T.; Kroll, A. V; Dehaini, D.; Zhou, J. R.; Kim, H. W.; Gao, W. W.; Lu, W. Y. et al. Nanoparticles camouflaged in platelet membrane coating as an antibody decoy for the treatment of immune thrombocytopenia. Biomaterials 2016, 111, 116–123.
DOI Google Scholar
71

Luk, B. T.; Fang, R. H.; Hu, C. M. J.; Copp, J. A.; Thamphiwatana, S.; Dehaini, D.; Gao, W. W.; Zhang, K.; Li, S. L.; Zhang, L. F. Safe and immunocompatible nanocarriers cloaked in RBC membranes for drug delivery to treat solid tumors. Theranostics 2016, 6, 1004–1011.
DOI Google Scholar
72

Lai, P. –Y.; Huang, R. –Y.; Lin, S. –Y.; Lin, Y. –H.; Chang, C. –W. Biomimetic stem cell membrane–camouflaged iron oxide nanoparticles for theranostic applications. RSC Adv. 2015, 5, 98222–98230.
DOI Google Scholar
73

Parodi, A.; Quattrocchi, N.; Van De Ven, A. L.; Chiappini, C.; Evangelopoulos, M.; Martinez, J. O.; Brown, B. S.; Khaled, S. Z.; Yazdi, I. K.; Enzo, M. V. et al. Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell–like functions. Nat. Nanotechnol. 2013, 8, 61–68.
DOI Google Scholar
74

Zhai, Y. H.; Su, J. H.; Ran, W.; Zhang, P. C.; Yin, Q.; Zhang, Z. W.; Yu, H. J.; Li, Y. P. Preparation and application of cell membrane–camouflaged nanoparticles for cancer therapy. Theranostics 2017, 7, 2575–2592.
DOI Google Scholar
75

Hu, Q. Y.; Sun, W. J.; Qian, C. G.; Wang, C.; Bomba, H. N.; Gu, Z. Anticancer platelet–mimicking nanovehicles. Adv. Mater. 2015, 27, 7043–7050.
DOI Google Scholar
76

Toledano Furman, N. E.; Lupu–Haber, Y.; Bronshtein, T.; Kaneti, L.; Letko, N.; Weinstein, E.; Baruch, L.; Machluf, M. Reconstructed stem cell nanoghosts: A natural tumor targeting platform. Nano Lett. 2013, 13, 3248–3255.
DOI Google Scholar
77

Gao, C. Y.; Lin, Z. H.; Jurado–Sánchez, B.; Lin, X. K.; Wu, Z. G.; He, Q. Stem cell membrane–coated nanogels for highly efficient in vivo tumor targeted drug delivery. Small 2016, 12, 4056–4062.
DOI Google Scholar
78

Xuan, M. J.; Shao, J. X.; Dai, L. R.; He, Q.; Li, J. B. Macrophage cell membrane camouflaged mesoporous silica nanocapsules for in vivo cancer therapy. Adv. Healthc. Mater. 2015, 4, 1645–1652.
DOI Google Scholar
79

Beduneau, A.; Ma, Z.; Grotepas, C. B.; Kabanov, A.; Rabinow, B. E.; Gong, N.; Mosley, R. L.; Dou, H.; Boska, M. D.; Gendelman, H. E. Facilitated monocyte–macrophage uptake and tissue distribution of superparmagnetic iron–oxide nanoparticles. PLoS One 2009, 4, e4343.
DOI Google Scholar
80

Pascucci, L.; Coccè, V.; Bonomi, A.; Ami, D.; Ceccarelli, P.; Ciusani, E.; Viganò, L.; Locatelli, A.; Sisto, F.; Doglia, S. M. et al. Paclitaxel is incorporated by mesenchymal stromal cells and released in exosomes that inhibit in vitro tumor growth: A new approach for drug delivery. J. Control. Release 2014, 192, 262–270.
DOI Google Scholar
81

Ohno, S. I.; Takanashi, M.; Sudo, K.; Ueda, S.; Ishikawa, A.; Matsuyama, N.; Fujita, K.; Mizutani, T.; Ohgi, T.; Ochiya, T. et al. Systemically injected exosomes targeted to EGFR deliver antitumor microrna to breast cancer cells. Mol. Ther. 2013, 21, 185–191.
DOI Google Scholar
82

Tian, Y. H.; Li, S. P.; Song, J.; Ji, T. J.; Zhu, M. T.; Anderson, G. J.; Wei, J. Y.; Nie, G. J. A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials 2014, 35, 2383–2390.
DOI Google Scholar
83

Alhasan, A. H.; Patel, P. C.; Choi, C. H. J.; Mirkin, C. A. Exosome encased spherical nucleic acid gold nanoparticle conjugates as potent microRNA regulation agents. Small 2014, 10, 186–192.
DOI Google Scholar
84

Berleman, J.; Auer, M. The role of bacterial outer membrane vesicles for intra–and interspecies delivery. Environ. Microbiol. 2013, 15, 347–354.
DOI Google Scholar
85

Gujrati, V.; Kim, S.; Kim, S. H.; Min, J. J.; Choy, H. E.; Kim, S. C.; Jon, S. Bioengineered bacterial outer membrane vesicles as cell–specific drug–delivery vehicles for cancer therapy. ACS Nano 2014, 8, 1525–1537.
DOI Google Scholar
86

Zhou, H.; Fan, Z. Y.; Lemons, P. K.; Cheng, H. A facile approach to functionalize cell membrane–coated nanoparticles. Theranostics 2016, 6, 1012–1022.
DOI Google Scholar
87

Xuan, M. J.; Shao, J. X.; Dai, L. R.; Li, J. B.; He, Q. Macrophage cell membrane camouflaged Au nanoshells for in vivo prolonged circulation life and enhanced cancer photothermal therapy. ACS Appl. Mater. Interfaces 2016, 8, 9610–9618.
DOI Google Scholar
88

Chen, Z.; Zhao, P. F.; Luo, Z. Y.; Zheng, M. B.; Tian, H.; Gong, P.; Gao, G. H.; Pan, H.; Liu, L. L.; Ma, A. Q. et al. Cancer cell membrane–biomimetic nanoparticles for homologous–targeting dual–modal imaging and photothermal therapy. ACS Nano 2016, 10, 10049–10057.
DOI Google Scholar
89

Sun, H. P.; Su, J. H.; Meng, Q. S.; Yin, Q.; Chen, L. L.; Gu, W. W.; Zhang, P. C.; Zhang, Z. W.; Yu, H. J.; Wang, S. L. et al. Cancer–cell–biomimetic nanoparticles for targeted therapy of homotypic tumors. Adv. Mater. 2016, 28, 9581–9588.
DOI Google Scholar
90

Fang, R. H.; Hu, C. M. J.; Luk, B. T.; Gao, W. W.; Copp, J. A.; Tai, Y. Y.; O'Connor, D. E.; Zhang, L. F. Cancer cell membrane–coated nanoparticles for anticancer vaccination and drug delivery. Nano Lett. 2014, 14, 2181–2188.
DOI Google Scholar
91

Kennedy, L. C.; Bear, A. S.; Young, J. K.; Lewinski, N. A.; Kim, J.; Foster, A. E.; Drezek, R. A. T cells enhance gold nanoparticle delivery to tumors in vivo. Nanoscale Res. Lett. 2011, 6, 283.
DOI Google Scholar
92

Sadhukha, T.; O'Brien, T. D.; Prabha, S. Nano–engineered mesenchymal stem cells as targeted therapeutic carriers. J. Control. Release 2014, 196, 243–251.
DOI Google Scholar
93

Choi, M. –R.; Stanton–Maxey, K. J.; Stanley, J. K.; Levin, C. S.; Bardhan, R.; Akin, D.; Badve, S.; Sturgis, J.; Robinson, J. P.; Bashir, R. et al. A cellular trojan horse for delivery of therapeutic nanoparticles into tumors. Nano Lett. 2007, 7, 3759–3765.
DOI Google Scholar
94

Roger, M.; Clavreul, A.; Venier–Julienne, M. C.; Passirani, C.; Sindji, L.; Schiller, P.; Montero–Menei, C.; Menei, P. Mesenchymal stem cells as cellular vehicles for delivery of nanoparticles to brain tumors. Biomaterials 2010, 31, 8393–8401.
DOI Google Scholar
95

Pang, L.; Qin, J.; Han, L. M.; Zhao, W. J.; Liang, J. M.; Xie, Z. Y.; Yang, P.; Wang, J. X. Exploiting macrophages as targeted carrier to guide nanoparticles into glioma. Oncotarget 2016, 7, 37081–37091.
DOI Google Scholar
96

Steinfeld, U.; Pauli, C.; Kaltz, N.; Bergemann, C.; Lee, H. H. T lymphocytes as potential therapeutic drug carrier for cancer treatment. Int. J. Pharm. 2006, 311, 229–236.
DOI Google Scholar
97

Tan, S. W.; Wu, T. T.; Zhang, D.; Zhang, Z. P. Cell or cell membrane–based drug delivery systems. Theranostics 2015, 5, 863–881.
DOI Google Scholar
98

Stephan, M. T.; Moon, J. J.; Um, S. H.; Bershteyn, A.; Irvine, D. J. Therapeutic cell engineering with surfaceconjugated synthetic nanoparticles. Nat. Med. 2010, 16, 1035–1041.
DOI Google Scholar
99

Cheng, H.; Kastrup, C. J.; Ramanathan, R.; Siegwart, D. J.; Ma, M. L.; Bogatyrev, S. R.; Xu, Q. B.; Whitehead, K. A.; Langer, R.; Anderson, D. G. Nanoparticulate cellular patches for cell–mediated tumoritropic delivery. ACS Nano 2010, 4, 625–631.
DOI Google Scholar
100

de Almeida, C. E. B.; Nascimento Alves, L.; Rocha, H. F.; Cabral–Neto, J. B.; Missailidis, S. Aptamer delivery of siRNA, radiopharmaceutics and chemotherapy agents in cancer. Int. J. Pharm. 2017, 525, 334–342.
DOI Google Scholar
101

Chen, S. Y.; Zhao, X. R.; Chen, J. Y.; Chen, J.; Kuznetsova, L.; Wong, S. S.; Ojima, I. Mechanism–based tumor–targeting drug delivery system. validation of efficient vitamin receptor–mediated endocytosis and drug release. Bioconjug. Chem. 2010, 21, 979–987.
DOI Google Scholar
102

Biabanikhankahdani, R.; Alitheen, N. B. M.; Ho, K. L.; Tan, W. S. PH–responsive virus–like nanoparticles with enhanced tumour–targeting ligands for cancer drug delivery. Sci. Rep. 2016, 6, 37891.
DOI Google Scholar
103

Kelley, E. G.; Albert, J. N. L.; Sullivan, M. O.; Epps, T. H., Ⅲ. Stimuli–responsive copolymer solution and surface assemblies for biomedical applications. Chem. Soc. Rev. 2013, 42, 7057–7071.
DOI Google Scholar
104

Greco, C. T.; Epps, T. H.; Sullivan, M. O. Mechanistic design of polymer nanocarriers to spatiotemporally control gene silencing. ACS Biomater. Sci. Eng. 2016, 2, 1582–1594.
DOI Google Scholar
105

Scott, A. M.; Allison, J. P.; Wolchok, J. D. Monoclonal antibodies in cancer therapy. Cancer Immun. 2012, 12, 14.
DOI Google Scholar
106

Sanna, V.; Pala, N.; Sechi, M. Targeted therapy using nanotechnology: Focus on cancer. Int. J. Nanomedicine 2014, 9, 467–483.
DOI Google Scholar
107

Anselmo, A. C.; Mitragotri, S. Nanoparticles in the clinic. Bioeng. Transl. Med. 2016, 1, 10–29.
DOI Google Scholar
108

Kennedy, P. J.; Oliveira, C.; Granja, P. L.; Sarmento, B. Antibodies and associates: Partners in targeted drug delivery. Pharmacol. Ther. 2017, 177, 129–145.
DOI Google Scholar
109

Bernardi, R. J.; Lowery, A. R.; Thompson, P. A.; Blaney, S. M.; West, J. L. Immunonanoshells for targeted photothermal ablation in medulloblastoma and glioma: An in vitro evaluation using human cell lines. J. Neurooncol. 2008, 86, 165–172.
DOI Google Scholar
110

Park, J. –H.; von Maltzahn, G.; Xu, M. J.; Fogal, V.; Kotamraju, V. R.; Ruoslahti, E.; Bhatia, S. N.; Sailor, M. J. Cooperative nanomaterial system to sensitize, target, and treat tumors. Proc. Natl. Acad. Sci. USA 2010, 107, 981–986.
DOI Google Scholar
111

Rink, J. S.; Plebanek, M. P.; Tripathy, S.; Thaxton, C. S. Update on current and potential nanoparticle cancer therapies. Curr. Opin. Oncol. 2013, 25, 646–651.
DOI Google Scholar
112

Akin, D.; Sturgis, J.; Ragheb, K.; Sherman, D.; Burkholder, K.; Robinson, J. P.; Bhunia, A. K.; Mohammed, S.; Bashir, R. Bacteria–mediated delivery of nanoparticles and cargo into cells. Nat. Nanotechnol. 2007, 2, 441–449.
DOI Google Scholar
113

Luo, C. H.; Huang, C. T.; Su, C. H.; Yeh, C. S. Bacteriamediated hypoxia–specific delivery of nanoparticles for tumors imaging and therapy. Nano Lett. 2016, 16, 3493–3499.
DOI Google Scholar
114

Wegmann, U.; Carvalho, A. L.; Stocks, M.; Carding, S. R. Use of genetically modified bacteria for drug delivery in humans: Revisiting the safety aspect. Sci. Rep. 2017, 7, 2294.
DOI Google Scholar
115

Blanco, E.; Shen, H. F.; Ferrari, M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat. Biotechnol. 2015, 33, 941–951.
DOI Google Scholar
116

Balmert, S. C.; Little, S. R. Biomimetic delivery with micro–and nanoparticles. Adv. Mater. 2012, 24, 3757–3778.
DOI Google Scholar
117

Meyer, R. A.; Sunshine, J. C.; Green, J. J. Biomimetic particles as therapeutics. Trends Biotechnol. 2015, 33, 514–524.
DOI Google Scholar
118
Kelly Scientific Publications. Advanced and Targeted DrugDelivery Market Segmentation, Analysis, & Forecastto 2021. https://www.researchandmarkets.com/research/m3gm88/advanced_and (accessed Mar 14, 2018).
119
Grand View Research. Nanomedicine Market Size Worth$350.8 Billion by 2025. https://www.grandviewresearch.com/press-release/global-nanomedicine-market (accessed Mar14, 2018).
120

Huang, C. C.; Chiang, C. K.; Lin, Z. H.; Lee, K. H.; Chang, H. T. Bioconjugated gold nanodots and nanoparticles for protein assays based on photoluminescence quenching. Anal. Chem. 2008, 80, 1497–1504.
DOI Google Scholar
Publication history
Copyright
Acknowledgements

Publication history

Received: 14 March 2018
Revised: 25 April 2018
Accepted: 26 April 2018
Published: 17 May 2018
Issue date: October 2018

Copyright

© Tsinghua University Press and Springer-Verlag GmbH Germany, part of Springer Nature 2018

Acknowledgements

Acknowledgements

This work was supported by the National Institute of General Medical Sciences of the National Institutes of Health under Award Number R35GM119659, and by a grant from the W.M. Keck Foundation. R. S. R. received support from an American Association of University Women Dissertation Fellowship. The content is solely the responsibility of the authors and does not necessarily reflect the views of the funding agencies.

Return